Nippon Shinyaku Co., Ltd. (NPPNY) and Eli Lilly Japan announced Friday that Eli Lilly Japan has received additional approval for Jaypirca to treat patients with chronic lymphocytic leukemia who are resistant to other BTK inhibitors.
This expanded approval of jaypirca, a bruton tyrosine kinase (BTK) inhibitor, is based on the positive data from a phase III study dubbed BRUIN-CLL-321.
Under the partnership agreement signed last year, Eli Lilly Japan handles supply of Jaypirca in Japan, while Nippon Shinyaku manages distribution, sales, and related information activities.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.